ONINTZA SAGREDO EZQUIOGA-rekin lankidetzan egindako argitalpenak (9)

2023

  1. Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet syndrome

    Neuropharmacology, Vol. 237

  2. Retinal Tissue Shows Glial Changes in a Dravet Syndrome Knock-in Mouse Model

    International Journal of Molecular Sciences, Vol. 24, Núm. 3

2022

  1. Editorial: Cannabinoids as potential treatment for neurological diseases

    Frontiers in Neuroscience

  2. Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

    Neuropharmacology, Vol. 205

2021

  1. Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments

    Frontiers in Molecular Neuroscience, Vol. 13

2018

  1. Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders

    Biochemical Pharmacology, Vol. 157, pp. 85-96

2016

  1. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome

    Pharmacology Research and Perspectives, Vol. 4, Núm. 2

2012

  1. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: Role of CB1 and CB2 receptors

    ACS Chemical Neuroscience

2011

  1. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

    Journal of Neuroscience Research, Vol. 89, Núm. 9, pp. 1509-1518